MOTS-c Is Moving Into Focus
Subject: MOTS-c Is Moving Into FocusBioPharma Research Brief — May 31, 2026
This week’s signal is clear: metabolic-pathway compounds ...
31
May
Monthly Archives: May 2026
24
May
Can SARMs Preserve Muscle on GLP-1 Weight Loss Drugs? (And Do You Need PCT After Them?)
Can SARMs Preserve Muscle on GLP-1 Weight Loss Drugs?This might be the most important emerging question in the SARMs space right now....
11
May
MOTS-c vs Metformin: Do They Target the Same Pathway? What Research Shows
A research-focused breakdown of MOTS-c and metformin — whether they target overlapping metabolic pathways, what the science says, and why this comparison went viral in nootropics communities.
11
May
Retatrutide vs Semaglutide vs Tirzepatide: What the Research Actually Shows
A research-focused comparison of retatrutide, semaglutide, and tirzepatide — mechanisms, trial data, and what the latest studies reveal about each compound.
07
May
MOTS-c vs Metformin: Do They Target the Same Pathway? (2026)
MOTS-c vs metformin — do they work through the same AMPK pathway? A research-based comparison of mechanisms, overlap, and why the nootropic and longevity communities are paying attention.
07
May
Retatrutide vs Semaglutide vs Tirzepatide: Which GLP-1 Compound Shows the Most Promise for Weight Loss Research?
Retatrutide vs semaglutide vs tirzepatide — compare clinical trial data, mechanisms, weight loss results, and side effects across the three leading GLP-1 compounds in 2026.
04
May
Ozempic Face and Muscle Loss: What Semaglutide Research Actually Shows (2026)
Does semaglutide cause Ozempic face and muscle loss? Research shows 25-40% of weight lost may be lean mass. Learn prevention strategies and the data.
04
May
Semaglutide for Weight Loss: Mechanism, Research, and What to Know (2026)
Semaglutide weight loss research — how GLP-1 agonists work, clinical trial results, sodium vs base form, and what happens when you stop.